Showing results (21-30 of 345) with videos related to
Sort By:
Pageof 35
Drug Safety|February 4, 2006
Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?Neil H ShearTherapeutic Drug Monitoring|November 27, 2002
Monitoring adverse drug reactions to sulfonamide antibiotics in human immunodeficiency virus-infected individualsManuela G Neuman, Izabella M Malkiewicz, Elizabeth J Phillips, et al.Molecular Diagnosis & Therapy|November 9, 2010
Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndromeAbdelbaset A Elzagallaai, Zahra Jahedmotlagh, Blanca R Del Pozzo-Magaña, et al.Journal of the American Academy of Dermatology|March 29, 2003
Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?Rochelle Mandelcorn, Neil H ShearDermatologic Therapy|October 23, 2009
Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrumSandra Knowles, Neil H ShearPaediatric Drugs|July 12, 2013
Cutaneous drug reactions in children: an updateKara Heelan, Neil H ShearAmerican Journal of Clinical Dermatology|June 9, 2012
Pharmacologic interventions for hidradenitis suppurativa: what does the evidence say?Raed Alhusayen, Neil H ShearExpert Opinion on Drug Safety|March 18, 2020
An update on the safety of apremilast for the treatment of plaque psoriasisEran Shavit, Neil H ShearAmerican Journal of Clinical Dermatology|April 8, 2011
A systematic approach to systemic contact dermatitis and symmetric drug-related intertriginous and flexural exanthema (SDRIFE): a closer look at these conditions and an approach to intertriginous eruptionsMonika Winnicki, Neil H ShearJournal of the American Academy of Dermatology|October 17, 2015
Scientific evidence for the use of current traditional systemic therapies in patients with hidradenitis suppurativaRaed Alhusayen, Neil H ShearPageof 35